Comparison of Administration of 8-Milligram and 4-Milligram Intranasal Naloxone by Law Enforcement During Response to Suspected Opioid Overdose

by Brian Shim | Apr 11, 2023 | News

In 2021, an 8-mg intranasal naloxone product was approved by the Food and Drug Administration; however, no studies have examined outcomes among persons who receive the 8-mg naloxone product and those who receive the usual 4-mg product…

US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals

by Brian Shim | Nov 2, 2022 | News

OTC Naloxone One Step Closer as Harm Reduction Therapeutics Initiates a Rolling Submission of its New Drug Application to U.S. FDA for RiVive™ for Emergency Treatment of Opioid Overdose

by Brian Shim | Oct 11, 2022 | News

Harm Reduction Therapeutics Signs Commercial Supply Agreement for Fast Tracked Naloxone Nasal Spray to Reverse Opioid Overdoses

by Brian Shim | Aug 11, 2022 | News

Harm Reduction Therapeutics Announces that its Naloxone Nasal Spray Met its Primary Endpoints in a Phase 1 Clinical Trial

by Brian Shim | Mar 1, 2022 | News